Dorfstrasse 29
Zug 6300
Switzerland
41 415108022
https://www.moonlaketx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 50
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Jorge Santos da Silva | Co-Founder, CEO & Director | 1,2M | N/D | 1978 |
Dr. Kristian Reich | Co-Founder & Chief Scientific Officer | 1,23M | N/D | 1966 |
Mr. Matthias Bodenstedt | Chief Financial Officer | 891,6k | N/D | 1988 |
Mr. Oliver Daltrop | Chief Technical Officer | N/D | N/D | N/D |
Nicolas Mosimann | General Counsel | N/D | N/D | N/D |
Luciana Marques | Director of HR, People & Culture | N/D | N/D | N/D |
Ms. Nuala Brennan | Chief Clinical Development Officer | N/D | N/D | N/D |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
L'ISS Governance QualityScore di MoonLake Immunotherapeutics al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.